Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders. The company’s mission focuses on addressing high unmet medical needs through innovative therapeutic solutions.
At the forefront of Keros’ pipeline is KER-050, a protein therapeutic product candidate aimed at treating low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes (MDS) and myelofibrosis. KER-050 is currently in Phase 2 clinical trials, with promising data presented at the 65th American Society of Hematology meeting showcasing its potential to ameliorate ineffective hematopoiesis and improve patient outcomes.
Another key product in development is KER-012, a small molecule being developed for the treatment of pulmonary arterial hypertension (PAH) and cardiovascular disorders. This candidate is also in Phase 2 trials and has shown encouraging preliminary results, particularly in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta.
KER-047, another small molecule candidate, targets anemia and the rare genetic disorder, fibrodysplasia ossificans progressiva (FOP). Currently in Phase 1 clinical trials, KER-047 aims to address significant gaps in treatment for these conditions.
Financially, Keros reported a net loss of $39.4 million for the third quarter of 2023, attributed to increased research and development efforts. Despite this, the company maintains a solid cash balance of $287.9 million as of September 30, 2023, expected to fund operations into the fourth quarter of 2025. The recent public offering of $120 million in common stock further strengthens their financial position.
Keros’ strategic partnerships and collaborations play a crucial role in its development strategy. The company’s agreement with Hansoh (Shanghai) Healthtech Co., Ltd. in 2021 for manufacturing technology transfer is a significant step towards commercial scalability.
The company’s commitment to advancing its pipeline and achieving clinical milestones is evident through its continuous updates and transparent communication with stakeholders. Upcoming milestones include updates on the KER-050 and KER-012 programs, reflecting Keros’ proactive approach in driving innovation and improving patient lives.
Keros Therapeutics remains a leader in leveraging the transforming growth factor-beta (TGF-β) family of proteins, aiming to provide meaningful and potentially disease-modifying benefits to patients.
Keros Therapeutics (Nasdaq: KROS) reported a net loss of $24.2 million for Q1 2022, up from $15.9 million in Q1 2021, primarily due to increased research and development and infrastructure costs. R&D expenses rose to $18.1 million compared to $11.5 million last year, while G&A expenses increased to $6.0 million from $4.3 million. The company has cash reserves of $228.6 million, expected to sustain operations through Q1 2024. Keros plans to share data from its Phase 2 trial of KER-050 in mid-2022 and initial results from the Phase 1 trial of KER-012 in Q2 2022.
Keros Therapeutics (KROS) reported its fourth quarter and full year 2021 financial results, highlighting a net loss of $6.9 million for Q4 and $58.7 million for the year, up from a $10.7 million loss in Q4 2020. Total revenue for 2021 was $20.1 million, attributed mainly to its strategic partnership with Hansoh for KER-050 in China, which brought in an $18 million upfront payment. Research and development expenses increased significantly to $18.8 million for Q4 as Keros advances clinical trials for KER-050 and KER-012. The company expects its cash reserves to last into Q1 2024.
Keros Therapeutics, Inc. (NASDAQ: KROS) announced that CEO Jasbir S. Seehra, Ph.D. will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 9:20 am ET. The presentation will be available via live webcast and will be archived on Keros’ investors' page for 90 days post-event. Keros specializes in developing treatments for hematological and musculoskeletal disorders, focusing on unmet medical needs with candidates like KER-050 for cytopenias, KER-047 for iron imbalance-related anemia, and KER-012 for bone loss disorders.
Keros Therapeutics, Inc. (KROS) has appointed Christopher Rovaldi as Chief Operating Officer, effective February 1, 2022. Rovaldi brings over 15 years of experience in developing TGF-β molecules across various diseases. His previous roles include senior leadership positions at Acceleron Pharma, and he has been a consultant since 2018. CEO Jasbir S. Seehra emphasized the importance of Rovaldi's expertise in advancing Keros' pipeline of novel treatments for hematological and musculoskeletal disorders. Keros focuses on addressing high unmet medical needs with its lead candidates KER-050, KER-047, and KER-012.
Keros Therapeutics (Nasdaq: KROS) has re-issued a press release from December 13, 2021, to correct typographical errors regarding its Phase 2 clinical trial of KER-050 for treating anemia in patients with myelodysplastic syndromes (MDS). The corrected document states that two cases of treatment-emergent adverse events, nausea and diarrhea, were related to KER-050. The trial aims to assess KER-050's safety and efficacy in various dosing cohorts, with initial data showing promising erythroid responses in evaluable patients. Keros continues to explore KER-050's potential in MDS and related disorders.
Keros Therapeutics, Inc. (KROS) presented additional data from its Phase 2 clinical trial of KER-050 for myelodysplastic syndromes (MDS) at the ASH Annual Meeting on December 13, 2021. The trial evaluates KER-050's efficacy in treating anemia due to MDS, with 50% of evaluable patients achieving an overall erythroid response. Phase 2 results indicate that KER-050 is generally well-tolerated, with no serious adverse events reported. Keros initiated dosing for Cohort 5 at 5.0 mg/kg, continuing to demonstrate promising advancements in hematologic therapies.
Keros Therapeutics has entered into a licensing agreement with Hansoh Pharma, granting them exclusive rights to develop and commercialize KER-050 in China, Hong Kong, and Macau. Keros will receive a $20 million upfront payment and is eligible for up to $170.5 million in milestone payments, as well as tiered royalties on net sales ranging from low double digits to high teens. This partnership aims to extend Keros' reach into one of the largest pharmaceutical markets globally and focuses on addressing hematological disorders.
Keros Therapeutics, a clinical-stage biopharmaceutical company, announced that its President and CEO, Jasbir S. Seehra, Ph.D., will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The presentation is available from November 22, 2021, at 10:00 a.m. ET, and will be archived on Keros' investor website for 90 days. Keros focuses on developing novel treatments for hematological and musculoskeletal disorders, with product candidates including KER-050 for cytopenias and KER-047 for anemia due to iron imbalance.
Keros Therapeutics, Inc. (Nasdaq: KROS) presented preclinical data on KER-012 at the AHA 2021 Scientific Sessions, showing its potential to reduce cardiac dysfunction and remodeling in a pulmonary arterial banding mouse model. The compound demonstrated a cardio-protective mechanism without increasing red blood cells or hemoglobin, suggesting it could treat pulmonary arterial hypertension (PAH) effectively. KER-012 aims to inhibit growth factors to promote bone growth and address conditions like osteoporosis. Initial data from a Phase 1 trial is expected in 2022.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that its CEO, Jasbir S. Seehra, Ph.D., will present at the Jefferies Virtual London Healthcare Conference on November 18, starting at 3:00 a.m. ET. The presentation will be accessible via the provided link and will be archived on Keros’ website for 90 days. Keros focuses on developing treatments for hematological and musculoskeletal disorders, with key products including KER-050 for cytopenias, KER-047 for iron imbalance-related anemia, and KER-012 for bone loss disorders.
FAQ
What is the current stock price of Keros Therapeutics (KROS)?
What is the market cap of Keros Therapeutics (KROS)?
What is Keros Therapeutics’ main focus?
What are the key products in Keros Therapeutics’ pipeline?
What recent achievements has Keros Therapeutics reported?
What is the financial condition of Keros Therapeutics?
How is Keros Therapeutics advancing its clinical trials?
What partnerships does Keros Therapeutics have?
What disorders does KER-050 target?
What is the significance of Fast Track designation for KER-050?
When can we expect updates on KER-012?
What role does the TGF-β family of proteins play in Keros Therapeutics’ research?
